|
|
|
|
|
24.03.26 - 12:06
|
Newron Presents 2025 Financial Results and Provides 2026 Outlook (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRMILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced its financial results and operational highlights for the business year ended December 31, 2025, and provided an outlook for 2026.
Highlights 2025:
Evenamide
Initiation of pivotal Phase III ENIGMA-TRS clinical program
In May, the Company announced regulatory approval for its pivotal Phase III ENIGMA-TRS program with evenamide as an add-on therapy in patients with treatment-resistant schizophrenia (TRS). The program comprises two pivotal studies, ENIGMA-TRS 1 and ENIGMA-TRS 2.
Post-period, in January 2026, Newron's partner EA Pharma (Eisai Group), who has the rights to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories, initiat...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.03.26 - 13:36
|
Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting (Business Wire)
|
|
|
George Garibaldi and Paolo Zocchi proposed as new independent, non-executive Board members
Patrick Langlois and Luca Benatti to step down after long-standing service
Full Annual General Meeting agenda to be published on March 24, 2026
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that Patrick Langlois and Luca Benatti, who have served on the Board of Directors for many years, will not be standing for re-election at the upcoming Annual General Meeting (AGM) of shareholders on April 23, 2026. Two highly experienced industry and financial experts, George Garibaldi and Paolo Zocchi, are proposed for election to Newron's Board as independent and non-executive directors.
Chris Martin, Chairman of the Board of Directors of Newron, commented on the resigning Board ...
|
|
|
|
|
|
|
17.02.26 - 13:36
|
Newron verschafft sich frisches Geld (GoingPublic)
|
|
|
Bildnachweis: Darya Pol – stock.adobe.com, stock3.com. Mit einem Kurssprung von in der Spitze 200 % zählte die Aktie von Newron Pharmaceuticals (IT0004147952) im Börsenjahr 2025 zu den Überfliegern unter den […]
Der Beitrag Newron verschafft sich frisches Geld erschien zuerst auf GoingPublic.de....
|
|
|
|
|
|
|
16.02.26 - 17:51
|
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LR
Proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development of evenamide as the potential first add-on therapy for treatment-resistant schizophreniaMILAN, Italy & MORRISTOWN, N.J.--(BUSINESS WIRE)--$NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”, or the “Company”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has entered into an agreement for the subscription of newly issued shares for proceeds of up to EUR 38 million with a group of existing and new shareholders from Europe and Asia, strengthening the Company's financial position as it advances the ENIGMA-TRS Phase III program.
Under the agreement, the investor group will initially subscribe to up to 779,624 newly issued shares at a subscription price of EUR 19.24 per sha...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
